Podcasts about personalised medicine

In this episode, host Prof. Jan Gutermuth explores with Prof. Christoffer Gebhardt the evolving landscape of melanoma prognosis. Together they discuss current strategies for predicting outcomes in melanoma patients, including clinical staging, histopathological features, and emerging molecular and genetic biomarkers. The conversation highlights how personalised medicine and novel diagnostic tools are shaping prognosis accuracy and guiding treatment decisions. Ideal for dermatologists, oncologists, and researchers, this #EADVPodcast episode underscores the importance of integrating science and patient care to improve long-term survival in melanoma. Passionate about Personalised Medicine? JEADV has an ongoing Call for Papers waiting for your contribution. Visit our website to know more: JEADV Call for papers: Personalised Medicine in Dermatology   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/

In this episode, Jonathan Sackier is joined by Philip Hamann, Consultant Rheumatologist at North Bristol NHS Trust, UK. Known for his engaging TEDx talks and innovative work with AI-driven healthcare apps, Hamann discusses how big data, personalised medicine, and a holistic approach are revolutionising care for patients with rheumatoid arthritis.  Timestamps:  00:00 – Introduction   01:01 – Using humour to communicate science   06:02 – ‘Living with Rheumatoid Arthritis': Hamann's award-winning app  14:43 – The cost of personalised medicine  19:07 – Real-world use of the app  26:05 – Importance of real-time data in rheumatology  33:10 – What does holistic care really mean?  40:07 – Hamann's three wishes for healthcare 

The Truth is HRT is SAFE to use for Menopause Relief and the benefits outweigh the risks. HRT can help rebuild bone, reduce the risk of Alzheimer's, heart disease, and colon cancer, and alleviate menopause symptoms like hot flushes. Nothing works like giving back what the body is missing. In this episode of Moving Through Menopause, Phillipa is joined by Dr. Malaika Woods, a Certified OBGYN and Functional Medicine Practitioner. FREE GIFT Download your Moving Through Menopause Guide https://precizion.co.uk/menopause-for-beginners/ We discuss the benefits of hormone replacement therapy (HRT) for menopause management and debunk misconceptions about its risks:

Valerie Gysberts, Functional and Nutritional Medicine Therapist, Beingwell Clinic, Melbourne, Australia and Jonathan Upfal, Integrated General Practitioner, National Institute of Integrative Medicine, Melbourne, Australia, discuss their medical practice with a diverse range of patients who have often been through the medical system but have seen no improvement and have complex conditions such as chronic fatigue, ADHD, and depression.  Use the following timestamps to navigate the episode: (00:00)-Introduction (2:36)-From pageant queen to Functional and Nutritional Medicine Therapist (8:10)-How the pair met (10:50)-Working with patients with chronic fatigue, ADHD, and depression (19:25)-Postnatal anxiety and depression (25:05)-Zinc and copper testing (29:50)-What can healthcare professionals do? (32:29)-Ozempic (36:40)-The importance of responsible use of social media (41:15)-Jonathan and Valerie's three wishes for healthcare

Pharmacogenomics plays a critical role in personalised medicine, as some adverse drug reactions are genetically determined. Adverse drugs reactions (ADRs) account for 6.5% of hospital admissions in the UK, and the application of pharmacogenomics to look at an individuals response to drugs can significantly enhance patient outcomes and safety. In this episode, our guests discuss how genomic testing can identify patients who will respond to medications and those who may have adverse reactions. We hear more about Genomics England's collaboration with the Medicines and Healthcare products Regulatory Agency in the Yellow Card Biobank and our guests discuss the challenges of implementing pharmacogenomics into the healthcare system. Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Anita Hanson, Research Matron and the Lead Research Nurse for clinical pharmacology at Liverpool University Hospitals NHS Foundation Trust, and Professor Bill Newman, Professor of translational genomic medicine at the Manchester Center for Genomic Medicine, and Professor Matt Brown, Chief Scientific Officer at Genomics England.   "I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record."   To learn more about Jane's lived experience with Stevens-Johnson syndrome, visit The Academy of Medical Sciences' (AMS) YouTube channel. The story, co-produced by Areeba Hanif from AMS, provides an in-depth look at Jane's journey. You can watch the video via this link: https://www.youtube.com/watch?v=v4KJtDZJyaA  Want to learn more about personalised medicine? Listen to our Genomics 101 episode where Professor Matt Brown explains what it is in less than 5 minutes: https://www.genomicsengland.co.uk/podcasts/genomics-101-what-is-personalised-medicine  You can read the transcript below or download it here: https://www.genomicsengland.co.uk/assets/documents/Podcast-transcripts/Can-genomic-testing-prevent-adverse-drug-reactions.docx   Vivienne: Hello and welcome to Behind the Genes.  Bill: What we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So, a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing.  Vivienne: My name's Vivienne Parry and I'm head of public engagement at Genomics England, and today we'll be discussing the critical role of pharmacogenomics in personalised medicine, highlighting its impact on how well medicines work, their safety, and on patient care. I'm joined today by Professor Bill Newman, professor of translational genomic medicine at the Manchester Centre for Genomic Medicine, Anita Hanson, research matron, a fabulous title, and lead research nurse for clinical pharmacology at the Liverpool University Hospital's NHS Foundation Trust, and Professor Matt Brown, chief scientific officer for Genomics England. And just remember, if you enjoy today's episode, we'd love your support, so please like, share and rate us on wherever you listen to your podcasts.  So, first question to you, Bill, what is pharmacogenomics?  Bill: Thanks Viv. I think there are lots of different definitions, but how I think of pharmacogenetics is by using genetic information to inform how we prescribe drugs, so that they can be safer and more effective. And we're talking about genetic changes that are passed down through families, so these are changes that are found in lots of individuals. We all carry changes in our genes that are important in how we transform and metabolise medicines, and how our bodies respond to them.  Vivienne: Now, you said pharmacogenetics. Is it one of those medicine things like tomato, tomato, or is there a real difference between pharmacogenetics and pharmacogenomics?  Bill: So, people, as you can imagine, do get quite irate about this sort of thing, and there are lots of people that would contest that there is a really big important difference. I suppose that pharmacogenetics is more when you're looking at single changes in a relatively small number of genes, whereas pharmacogenomics is a broader definition, which can involve looking at the whole genome, lots of genes, and also whether those genes are switched on or switched off, so the expression levels of those genes as well would encompass pharmacogenomics. But ultimately it's using genetic information to make drug prescription safer and more effective.  Vivienne: So, we're going to call it pharmacogenomics and we're talking about everything, that's it, we'll go for it. So Matt, just explain if you would the link between pharmacogenomics and personalised medicine. And I know that you've done a big Genomics 101 episode about personalised medicine, but just very briefly, what's the link between the two?  Matt: So, personalised medicine's about using the right dose of the right drug for the right individual. And so pharmacogenomics helps you with not only ensuring that you give a medication which doesn't cause problems for the person who receives it, so an adverse drug reaction, but also that they're actually getting the right dose. Of course, people's ability to metabolise, activate and respond to drugs genetically is often genetically determined, and so sometimes you need to adjust the dose up or down according to a person's genetic background.  Vivienne: Now, one of the things that we've become very aware of is adverse drug reactions, and I think they account for something like six and a half percent of all hospital admissions in the UK, so it's absolutely huge. Is that genetically determined adverse drug reactions?  Matt: So, the answer to that is we believe so. There's quite a bit of data to show that you can reduce the risk of people needing a hospital admission by screening genetic markers, and a lot of the very severe reactions that lead to people being admitted to hospital are very strongly genetically determined. So for example, there are HLA types that affect the risk of adverse drug reactions to commonly used medications for gout, for epilepsy, some HIV medications and so on, where in many health services around the world, including in England, there are already tests available to help prevent those leading to severe reactions. It's likely though that actually the tests we have available only represent a small fraction of the total preventable adverse drug reactions were we to have a formal pre-emptive pharmacogenomics screening programme.  Vivienne: Now, I should say that not all adverse drug reactions are genetic in origin. I mean, I remember a rather nasty incident on the night when I got my exam results for my finals, and I'd actually had a big bee sting and I'd been prescribed antihistamines, and I went out and I drank rather a lot to celebrate, and oh my goodness me, I was rather ill [laughter]. So, you know, not all adverse drug reactions are genetic in origin. There are other things that interact as well, just to make that clear to people.  Matt: Yes, I think that's more an interaction than an adverse drug reaction. In fact frankly, the most common adverse drug reaction in hospitals is probably through excess amounts of water, and that's not medically determined, that's the prescription.  Vivienne: Let me now come to Anita. So, you talk to patients all the time about pharmacogenomics in your role. You've been very much involved in patient and public involvement groups at the Wolfson Centre for Personalised Medicine in Liverpool. What do patients think about pharmacogenomics? Is it something they welcome?  Anita: I think they do welcome pharmacogenomics, especially so with some of the patients who've experienced some of the more serious, life threatening reactions. And so one of our patients has been doing some work with the Academy of Medical Sciences, and she presented to the Sir Colin Dollery lecture in 2022, and she shared her story of having an adverse drug reaction and the importance of pharmacogenomics, and the impact that pharmacogenomics can have on patient care.  Vivienne: Now, I think that was Stevens-Johnson syndrome. We're going to hear in a moment from somebody who did experience Stevens-Johnson's, but just tell us briefly what that is.  Anita: Stevens-Johnson syndrome is a potentially life threatening reaction that can be caused by a viral infection, but is more commonly caused by a medicine. There are certain groups of medicines that can cause this reaction, such as antibiotics or anticonvulsants, nonsteroidal anti-inflammatories, and also a drug called allopurinol, which is used to treat gout. Patients have really serious side effects to this condition, and they're often left with long-term health complications. The morbidity and mortality is considerable as well, and patients often spend a lot of time in hospital and take a long time to recover.   Vivienne: And let's now hear from Jane Burns for someone with lived experience of that Stevens-Johnson syndrome. When Jane Burns was 19, the medicine she took for her epilepsy was changed.  Jane: I remember waking up and feeling really hot, and I was hallucinating, so I was taken to the Royal Liverpool Hospital emergency department by my parents. When I reached A&E, I had a temperature of 40 degrees Celsius. I was given Piriton and paracetamol, and the dermatologist was contacted. My mum had taken my medication to hospital and explained the changeover process with my epilepsy medication. A decision was made to discontinue the Tegretol and I was kept in for observation. Quite rapidly, the rash was changing. Blisters were forming all over my body, my mouth was sore and my jaw ached. My temperature remained very high. It was at this point that Stevens-Johnson syndrome, or SJS, was diagnosed.  Over the next few days, my condition deteriorated rapidly. The rash became deeper in colour. Some of the blisters had burst, but some got larger. I developed ulcers on my mouth and it was extremely painful. I started to lose my hair and my fingernails. As I had now lost 65 percent of my skin, a diagnosis of toxic epidermal necrolysis, or TEN, was made. Survivors of SJS TEN often suffer with long-term visible physical complications, but it is important to also be aware of the psychological effects, with some patients experiencing post-traumatic stress disorder. It's only as I get older that I realise how extremely lucky I am to have survived. Due to medical and nursing expertise, and the research being conducted at the time, my SJS was diagnosed quickly and the medication stopped. This undoubtedly saved my life.  Vivienne: Now, you've been looking at the development of a passport in collaborating with the AMS and the MHRA. Tell me a bit more about that.  Anita: Yes, we set up a patient group at the Wolfson Centre for Personalised Medicine approximately 12 years ago, and Professor Sir Munir Pirmohamed and I, we wanted to explore a little bit more about what was important to patients, really to complement all the scientific and clinical research activity within pharmacogenomics. And patients recognised that, alongside the pharmacogenomic testing, they recognised healthcare professionals didn't really have an awareness of such serious reactions like Stevens-Johnson syndrome, and so they said they would benefit from having a My SJS Passport, which is a booklet that can summarise all of the important information about their care post-discharge, and this can then be used to coordinate and manage their long-term healthcare problems post-discharge and beyond. And so this was designed by survivors for survivors, and it was then evaluated as part of my PhD, and the findings from the work suggest that the passport is like the patient's voice, and it really does kind of validate their diagnosis and raises awareness of SJS amongst healthcare professionals. So, really excellent findings from the research, and the patients think it's a wonderful benefit to them.  Vivienne: So, it's a bit like a kind of paper version of the bracelet that you sometimes see people wearing that are on steroids, for instance.  Anita: It is like that, and it's wonderful because it's a handheld source of valuable information that they can share with healthcare professionals. And this is particularly important if they're admitted in an emergency and they can't speak for themselves. And so the passport has all that valuable information, so that patients aren't prescribed that drug again, so it prevents them experiencing a serious adverse drug reaction again.   Vivienne: So, Stevens-Johnson, Bill, is a really scary side effect, but what about the day to day benefits of pharmacogenomics for patients?  Bill: So, what we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing.   And it's not just in terms of side effects. It's in terms of the effectiveness of the medicine. Because if a person is prescribed a medicine that doesn't or isn't going to work for them then it can take them longer to recover, to get onto the right medicine. That can have all sorts of detrimental effects. And so when we're thinking about introducing pharmacogenetics more broadly rather than just on a single drug or a single gene basis, we're thinking about that for common drugs like antidepressants, painkillers, statins, the drugs that GPs are often prescribing on a regular basis to a whole range of patients.  Vivienne: So, to go back to you, Anita, we're really talking about dose here, aren't we, whether you need twice the dose or half the dose depending on how quickly your body metabolises that particular medicine. How do patients view that?  Anita: Well, the patient in question who presented for the Academy of Medical Sciences, I mean, her take on this was, she thinks pharmacogenetics is wonderful because it will allow doctors and nurses to then prescribe the right drug, but also to adapt the dose accordingly to make sure that they get the best outcome, which provides the maximum benefit while also minimising any potential harm. And so from her perspective, that was one of the real benefits of pharmacogenomics. But she also highlighted about the benefits for future generations, the fear of her son taking the same medicine and experiencing the same reaction. And so I think her concerns were, if we have pharmacogenetic testing for a panel of medicines, as Bill mentioned then, then perhaps this would be fantastic for our children as they grow up, and we can identify and predict and prevent these type of reactions happening to future generations.  Vivienne: And some of these drugs, Bill, are really very common indeed, something like codeine. Just tell us about codeine, ‘cos it's something – whenever I tell this to friends [laughter], they're always completely entranced by the idea that some people don't need nearly as much codeine as others.  Bill: Yeah, so codeine is a drug that's very commonly used as a painkiller. To have its real effect, it needs to be converted in the body to a different drug called morphine, and that is done by an enzyme which is made by a gene called CYP2D6. And we all carry changes in CYP2D6, and the frequency of those variants, whether they make the gene work too much or whether they make it work too little, they vary enormously across the world, so that if you go to parts of Africa, about 30 percent of the population will make more of the CYP2D6, and so they will convert the codeine much more quickly, whereas if you go to the UK, maybe up to ten percent of the white population in the UK just won't be converting codeine to morphine at all, so they won't get any benefit from the drug. So at both ends, you have some people that don't respond and some people that respond a little bit too much so that they need either an alternative drug or they need a different dose.  Vivienne: So, all those people who say, you know, “My headache hasn't been touched by this painkiller,” and we say, “What a wimp you're being,” actually, it's to do with genetics.  Bill: Yeah, absolutely. There's a biological reason why people don't – not for everybody, but for a significant number of people, that's absolutely right, and we can be far more tailored in how we prescribe medication, and get people onto painkillers that work for them much more quickly.  Vivienne: And that's so interesting that it varies by where you come from in the world, because that means we need to give particular attention – and I'm thinking, Anita, to working with patients from different community groups, to make sure that they understand the need for pharmacogenomics.  Anita: I think that's really important, Vivienne, and I think we are now having discussions with the likes of Canada SJS awareness group, and also people have been in touch with me from South Africa because people have requested the passport now to be used in different countries, because they think it's a wonderful tool, and it's about raising awareness of pharmacogenomics and the potential benefits of that, and being able to share the tools that we've got to help patients once they've experienced a serious reaction.  Vivienne: So, pharmacogenomics clearly is important in the prevention of adverse drug reactions, better and more accurate prescribing, reduced medicines wastage. Does this mean that it's also going to save money, Bill, for the NHS?  Bill: Potentially. It should do if it's applied properly, but there's lots of work to make sure that not only are we using the right evidence and using the right types of tests in the laboratory, but we're getting the information to prescribers, so to GPs, to pharmacists, to hospital doctors, in a way that is understandable and meaningful, such that they can then act upon that information. So, the money will only be saved and then can be reused for healthcare if the whole process and the whole pathway works, and that information is used effectively.  Vivienne: So, a lot of research to make sure that all of that is in place, and to demonstrate the potential cost savings.  Bill: Yes. I mean, there are very nice studies that have been done already in parts of the world that have shown that the savings that could be accrued for applying pharmacogenetics across common conditions like depression, like in patients to prevent secondary types of strokes, are enormous. They run into hundreds of millions of pounds or dollars. But there is an initial investment that is required to make sure that we have the testing in place, that we have the digital pathways to move the information in place, and that there's the education and training, so that health professionals know how to use the information. But the potential is absolutely enormous.  Vivienne: Matt, can I turn now to the yellow card. So, people will be very familiar with the yellow card system. So, if you have an adverse reaction, you can send a yellow card in – I mean, literally, it is a yellow card [laughter]. It does exactly what it says on the tin. You send a yellow card to the MHRA, and they note if there's been an adverse effect of a particular medicine. But Genomics England is teaming up with the MHRA to do something more with yellow cards, and we're also doing this with the Yellow Card Biobank. Tell us a bit more.  Matt: So, yellow card's a great scheme that was set up decades ago, initially starting off, as you said, with literally yellow cards, but now actually most submissions actually come online. And it's important to note that submissions can come not just from healthcare providers, but majority of submissions actually come from patients themselves, and that people should feel free, if they feel they've had an adverse drug reaction, to report that themselves rather than necessarily depending on a medical practitioner or the healthcare provider to create that report. So, Genomics England is partnering with the MHRA in building what's called the Yellow Card Biobank, the goal of which is to identify genetic markers for adverse drug reactions earlier than has occurred in the past, so that we can then introduce genetic tests to prevent these adverse drug reactions much sooner than has occurred previously.   So, what we're doing is basically at the moment we're doing a pilot, but the ultimate plan is that in future, patients who report a serious adverse drug reaction through the Yellow Card Biobank will be asked to provide a sample, a blood sample, that we then screen. We do a whole genome sequence on it, and then combine these with patients who've had like adverse drug reactions and identify genetic markers for that adverse drug reaction medication earlier, that can then be introduced into clinical practice earlier. And this should reduce by decades the amount of time between when adverse drug reactions first start occurring with medications and us then being able to translate that into a preventative mechanism.  Vivienne: And will that scheme discover, do you think, new interactions that you didn't know about before? Or do you expect it to turn up what you already know about?  Matt: No, I really think there's a lot of discovery that is yet to happen here. In particular, even for drugs that we know cause adverse drug reactions, mostly they've only been studied in people of European ancestry and often in East Asian ancestry, but in many other ancestries that are really important in the global population and in the UK population, like African ancestry and South Asian ancestries, we have very little data. And even within Africa, which is an area which is genetically diverse as the rest of the world put together, we really don't know what different ethnicities within Africa, actually what their genetic background is with regard to adverse drug reactions.  The other thing I'd say is that there are a lot of new medications which have simply not been studied well enough. And lastly, that at the moment people are focused on adverse drug reactions being due to single genetic variants, when we know from the model of most human diseases that most human diseases are actually caused by combinations of genetic variants interacting with one another, so-called common disease type genetics, and that probably is similarly important with regard to pharmacogenomics as it is to overall human diseases. That is, it's far more common that these are actually due to common variants interacting with one another rather than the rare variants that we've been studying to date.  Vivienne: So, it's a kind of cocktail effect, if you like. You know, you need lots of genes working together and that will produce a reaction that you may not have expected if you'd looked at a single gene alone.  Matt: That's absolutely correct, and there's an increasing amount of evidence to show that that is the case with medications, but it's really very early days for research in that field. And the Yellow Card Biobank will be one of many approaches that will discover these genetic variants in years to come.  Vivienne: Now, Matt's a research scientist. Bill, you're on the frontline in the NHS. How quickly can this sort of finding be translated into care for people in the NHS?  Bill: So, really quickly is the simple answer to that, Viv. If we look at examples from a number of years ago, there's a drug called azathioprine that Matt has used lots in some of his patients. In rheumatology, it's used for patients with inflammatory bowel disease. And the first studies that showed that there was a gene that was relevant to having bad reactions to that drug came out in the 1980s, but it wasn't until well into this century, so probably 30-plus years later that we were routinely using that test in clinical medicine. So, there was an enormous lot of hesitancy about adopting that type of testing, and a bit of uncertainty. If you move forward to work that our colleague Munir Pirmohamed in Liverpool has done with colleagues in Australia like Simon Mallal around HIV medicine, there was this discovery that a drug called abacavir, that if you carried a particular genetic change, that you had a much higher risk of having a really severe reaction to that. The adoption from the initial discovery to routine, worldwide testing happened within four years.   So, already we've seen a significant change in the appetite to move quickly to adopt this type of testing, and I see certainly within the NHS and within other health systems around the world, a real desire to adopt pharmacogenetics into routine clinical practice quickly and at scale, but also as part of a broader package of care, which doesn't just solely focus on genetics, but thinks about all the other parts that are important in how we respond to medication. So, making sure we're not on unusual combinations of drugs, or that we're taking our medicine at the right time and with food or not with food, and all of those other things that are really important. And if you link that to the pharmacogenetics, we're going to have a much safer, more effective medicines world.  Vivienne: I think one of the joys of working at Genomics England is that you see some of this work really going into clinical practice very fast indeed. And I should say actually that the Wolfson Centre for Personalised Medicine, the PPI group that Anita looks after so well, they've been very important in recruiting people to Yellow Card Biobank. And if anyone's listening to this, Matt, and wants to be part of this, how do they get involved? Or is it simply through the yellow card?  Matt: So at the moment, the Yellow Card Biobank is focusing on alopurinol.   Vivienne: So, that's a medicine you take for gout.  Matt: Which I use a lot in my rheumatology clinical practice. And direct acting oral anticoagulants, DOACs, which are used for vascular disease therapies and haemorrhage as a result of that. So, the contact details are available through the MHRA website, but I think more importantly, it's just that people be aware of the yellow card system itself, and that if they do experience adverse drug reactions, that they do actually complete a report form, ‘cos I think still actually a lot of adverse drug reactions go unreported.  Vivienne: I'm forgetting of course that we see Matt all the time in the Genomics England office and we don't think that he has any other home [laughter] than Genomics England, but of course he still sees some patients in rheumatology clinic. So, I want to now look to the future. I mean, I'm, as you both know, a huge enthusiast for pharmacogenomics, ‘cos it's the thing that actually, when you talk to patients or just the general public, they just get it straight away. They can't think why, if you knew about pharmacogenomics, why you wouldn't want to do it. But it's not necessarily an easy thing to do. How can we move in the future, Bill, to a more proactive approach for pharmacogenomics testing? Where would we start?  Bill: Yes, so I think we've built up really good confidence that pharmacogenetics is a good thing to be doing. Currently, we're doing that predominantly at the point when a patient needs a particular medicine. That's the time that you would think about doing a genetic test. And previously, that genetic test would only be relevant for that specific drug. I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record. That's what we'd call pre-emptive pharmacogenetic testing, and I think that's the golden land that we want to reach.  Vivienne: So for instance, I might have it on my NHS app, and when I go to a doctor and they prescribe something, I show my app to the GP, or something pops up on the GP's screen, or maybe it's something that pops up on the pharmacist's screen.  Bill: I think that's right. I think that's what we're looking to get to that point. We know that colleagues in the Netherlands have made some great progress at developing pathways around that. There's a lot of public support for that. And pharmacists are very engaged in that. In the UK, the pharmacists, over the last few years, have really taken a very active role to really push forward this area of medicine, and this should be seen as something that is relevant to all people, and all health professionals should be engaged with it.  Vivienne: And on a scale of one to ten, how difficult is it going to be to implement in the NHS?  Bill: So, that's a difficult question. I think the first thing is identifying what the challenges are. So I have not given you a number, I've turned into a politician, not answered the question. So, I think what has happened over the last few years, and some of our work within the NHS Network of Excellence in pharmacogenetics and some of the other programmes of work that have been going on, is a really good, honest look at what it is we need to do to try to achieve pharmacogenetics implementation and routine use. I don't think the challenge is going to be predominantly in the laboratory. I think we've got phenomenal laboratories. I think we've got great people doing great genetic testing. I think the biggest challenges are going to be about how you present the data, and that data is accessible. And then ensuring that health professionals really feel that this is information that isn't getting in the way of their clinical practice, but really making a difference and enhancing it, and of benefit both to the healthcare system but more importantly to the patients.  Vivienne: Now, when I hear you both talk, my mind turns to drug discovery and research, and Matt, I'm quite sure that that's right at the top of your mind. Tell us how pharmacogenomics can help in drug discovery and research.  Matt: So, pharmacogenomics, I think actually just genetic profiling of diseases in itself just to start off with is actually a really good way of identifying new potential therapeutic targets, and also from derisking drug development programmes by highlighting likely adverse drug reactions of medications that are being considered for therapeutic trials, or targets that are being considered for therapeutic development. Pharmacogenomics beyond that is actually largely about – well, it enables drug development programmes by enabling you to target people who are more likely to respond, and avoid people who are more likely to have adverse drug reactions. And so that therapeutic index of the balance between likely efficacy versus likely toxicity, genetics can really play into that and enable medications to be used where otherwise they might have failed.  This is most apparent I think in the cancer world. A classic example there, for example, is the development of a class of medications called EGFR inhibitors, which were developed for lung cancer, and in the initial cancer trials, actually were demonstrated to be ineffective, until people trialled them in East Asia and found that they were effective, and that that turns out to be because the type of cancers that respond to them are those that have mutations in the EGFR gene, and that that's common in East Asians. We now know that, wherever you are in the world, whether you're East Asian or European or whatever, if you have a lung adenocarcinoma with an EGFR mutation, you're very likely to respond to these medications. And so that pharmacogenomic discovery basically rescued a class of medication which is now probably the most widely used medication for lung adenocarcinomas, so a huge beneficial effect. And that example is repeated across multiple different cancer types, cancer medication types, and I'm sure in other fields we'll see that with expansive new medications coming in for molecularly targeted therapies in particular.  Vivienne: So, smaller and more effective trials rather than larger trials that perhaps seem not to work but actually haven't been tailored enough to the patients that are most likely to benefit.  Matt: Yeah, well, particularly now that drug development programmes tend to be very targeted at specific genetic targets, pharmacogenetics is much more likely to play a role in identifying patients who are going to respond to those medications. So, I think many people in the drug development world would like to see that, for any significant drug development programme, there's a proper associated pharmacogenomic programme to come up with molecular markers predicting a response.  Vivienne: We're going to wrap up there. Thank you so much to our guests, Bill Newman, Anita Hanson, Matt Brown, and our patient Jane Burns. Thank you so much for joining us today to discuss pharmacogenomics in personalised medicine, and the benefits, the challenges and the future prospects for integrating pharmacogenomics into healthcare systems. And if you'd like to hear more podcasts like this, please subscribe to Behind the Genes. It's on your favourite podcast app. Thank you so much for listening. I've been your host, Vivienne Parry. This podcast was edited by Bill Griffin at Ventoux Digital and produced by the wonderful Naimah. Bye for now. 

In this episode, we welcome Dr. Almut Heinken, Junior Professor at the INSERM Institute of Nutrition, Genetics, Environment, and Risk Exposure at Université de Lorraine. Her work focuses on multiscale metabolic modelling of host-microbiome interactions and their role in human health. She has contributed to the development of genome-scale reconstructions of human microbes, known as the AGORA resource. Almut has also developed tools to build personalised microbiome models and applied these models to inflammatory bowel disease, Parkinson's Disease, and colorectal cancer. She is currently working on modelling the interactions between diet, the microbiome, and the epigenome. Tune in to this exciting discussion!

This month, our featured resources focus on diagnostic advancements in autoimmune disease, the critical importance of early Lyme detection, and innovative strategies for improving overall health: 

In this explainer episode, we've asked Professor Matt Brown, Chief Scientific Officer at Genomics England, to explain what personalised medicine is and how it could change the way we treat genetic conditions and cancer. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, feel free to contact us on info@genomicsengland.co.uk. You can read the transcript below or download it here: https://files.genomicsengland.co.uk/documents/Podcast-transcripts/What-is-personalised-medicine.docx Naimah: What is personalised medicine? I'm joined by Matt Brown, chief scientific officer for Genomics England, to find out more. So, first of all, Matt, can you tell me, what is personalised medicine?   Matt: So, personalised medicine is about giving the right dose of a medicine and the right medicine to the right person. So, it's exactly the opposite of one size fits all. It's what doctors have been trying to do ever since we had effective medicines, that is generally looking at the patient, what disease have they got, what factors are there about the patient that can help judge what dose they should give and for how long, of which medicine.   Naimah: So, people often refer to this as precision medicine. Is this the same thing?   Matt: Generally, the two terms are used interchangeably. I think precision medicine is more specifically about the dose perhaps, but effectively they both mean the right medicine at the right dose for the right person.   Naimah: And how can we predict what treatment will suit each individual patient best?   Matt: Well, to some extent, of course, this depends on the disease the patient actually has. We also know from a patient's history how they've reacted to similar medications in the past. So for example, some patients have lots of problems with anti-inflammatories, other patients don't, so if you give an anti-inflammatory to somebody who's had problems with them before, you're likely to cause the same problems all over again. So nowadays, we have much, much better ways, other than trial and error, to predict what treatment will suit a patient best, and in particular, development of genetic markers to look at how their condition is going to respond best, and how the patient is going to tolerate the medicine you give them, and what dose you should be giving them.   Naimah: How could personalised medicine change the way we treat genetic conditions and cancer?   Matt: So, I'll talk about cancer first up. In the past, we used to treat cancers based on the organ from which the cancer actually arose, and the more we've learnt about what the genetic mutations are that cause cancers, the more cancer treatments are being decided based on the genetic mutation which is driving the cancer, and this has proven to be more effective than just looking at the organ from which the cancer arose. It turns out then that some medications which were only being used for specific cancers, are actually useful across multiple cancers that are driven by the same genetic mutations.   In lots of other common diseases though, we now know a lot about genetic variants which predispose people to adverse drug reactions, and so we can use genetic tests to predict who's going to get those adverse drug reactions and avoid them. And similarly, we also know about genetic determinants of how people metabolise and, in many cases, activate medications, and that helps us a lot learning about what dose to give people.   Naimah: And how far away are we from seeing this routinely in clinical care?   Matt: We are seeing it in routine clinical care in some pretty narrow settings. So, there are genetic tests available for enzymes which are involved in activation of particular chemotherapy 5 agents. So, DPYD testing, for example, is widely used to predict people's likely response to a class of chemotherapy agent called fluoropyrimidines, or 5-Fluorouracil is a common one, and the genetic test basically picks out a group of people, a small number of people who are likely to have severe adverse drug reactions to that class of medication, and that's been a really big success.   We also use it for picking some other severe adverse drug reactions to medications like gout medications, HIV medications and so on, but generally it's pretty narrow. What we want to get to the point is where we have people tested in advance of them needing medications, so that when they go to the doctor to be seen about a particular condition, the doctor already has the genetic test available to them, so the doctor can say if the medication is safe and what dose to use. This is what we call pre-emptive testing.   Naimah: That was Matt Brown explaining what is personalised medicine. If you'd like to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk. Thank you for listening. 

This edition of Airing Pain focuses on the treatment of pain, the importance of catering treatment to a person's individual genetic makeup, and why addressing the psychological dimensions of pain is crucial in treating it effectively.  The process of finding a medication or treatment that works for a person often involves a lot of trial and error, which can be a frustrating process for someone to go through. This process can be side-stepped through the use of personalised medicine, where information about a person's genetic makeup is used to tailor and optimise their treatment so it is as effective as possible. Although medication is oftentimes a vital part of treating pain, incorporating psychological treatment alongside medication can be hugely beneficial when it comes to making pain management better for those living with acute or chronic pain. Changing how someone thinks about pain can enhance their response to the physical components of the treatment they receive. Our contributors for this edition discuss the ways in which the treatment of pain can be made more effective for people by incorporating personalised medicine or psychological treatments into a person's care plan. Please leave us a review on this platform or give feedback via our Airing Pain survey. Contributors: Professor Tony Dickenson, Professor of Neuropharmacology at University College London. Dr. Beth Darnall, PhD, Professor of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine. Director, Stanford Pain Relief Innovations Lab. Professor Irene Tracey, Vice Chancellor of the University of Oxford and a Professor of Anaesthetic Neuroscience in the Nuffield Department of Clinical Neurosciences. Read transcript Thanks: This edition of was made possible thanks to funding from the Guy Fawkes Charitable Trust and support from the British Pain Society. Time Stamps: 1:11 Paul introduces Professor Tony Dickenson,who he spoke to at the British Pain Society Annual Scientific Meeting 2022. 3:21 Professor Tony Dickenson discusses ‘precision medicine', ‘personalised medicine', and how looking at peoples' genetic makeup can help medical professionals treat pain more effectively.  14:21 Paul introduces Dr Beth Darnall, who he spoke to at the British Pain Society Annual Scientific Meeting 2023. 14:54 Dr Beth Darnall explains the psychological components of how people experience pain. 20:24 Paul introduces Professor Irene Tracy, who he spoke to at the British Pain Society Annual Scientific Meeting 2023.  20:57 Dr Irene Tracy discusses the work she's done on neuroimaging and how the human brain constructs the experience of pain.  23:22 Paul and Dr Tracy talk about what neuroimaging tells us about the multidimensional way the human brain reacts to pain. 26:06 Beginning of discussion about Empowered Relief, a psychology-based intervention that provides people with skills and tools to help manage their acute or chronic pain.  26:31 Dr Beth Darnall discusses the psychological side of treating pain and how empowered relief is used to help people manage their pain. 29:10 Dr Beth Darnall talks about the psychological tools people learn through Empowered Relief and how they help with pain management.    Additional Resources: Airing Pain 100: Glasgow Pain Education Sessions Empowered Relief  Pain Matters 80: What treatment really works 

Coming 10 April: This edition of Airing Pain focuses on the treatment of pain, the importance of catering treatment to a person's individual genetic makeup, and why addressing the psychological dimensions of pain is crucial in treating it effectively.   Our contributors for this edition discuss the ways in which the treatment of pain can be made more effective for people by incorporating personalised medicine or psychological treatments into a person's care plan.  This edition will be funded by the Guy Fawkes Charitable Trust and was created with support from the British Pain Society. Contributors:  Professor Tony Dickenson, Professor of Neuropharmacology at University College London  Dr. Beth Darnall, PhD, Professor of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine. Director, Stanford Pain Relief Innovations Lab. Professor Irene Tracey, Vice Chancellor of the University of Oxford and a Professor of Anaesthetic Neuroscience in the Nuffield Department of Clinical Neurosciences. 

There's no doubt new advances in science and technology are having a huge impact on the way we live our lives these days. From Big Data and artificial intelligence to genomics and wearable devices that track daily our activity. Of course, medicine is no exception. All of these technological steps forward are pointing healthcare towards a coming era of personalised medicine that focusses more directly on the needs of the individual patient. In this episode we speak to Professor Sir Munir Pirmohamed, David Weatherall Chair in Medicine at the University of Liverpool, NHS Chair of Pharmacogenetics, and a consultant physician at the Royal Liverpool University Hospital. He tells us how advances in medical techniques such as genetic screening and a focus on patients' differing reactions to treatment can go beyond a one-drug-fits-all approach to healthcare and even treat diseases before symptoms appear. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Is it ever too late to learn? What is the science behind how to change your brain? And what if the key to reshaping our brains and altering our perspectives lies within our grasp, regardless of our years?This is the fascinating life's work of today's esteemed guest, Dr. Lara Boyd.Dr. Lara Boyd, a Neuroscientist and Physical Therapist at the University of British Columbia, is an expert in mapping how our behaviours, environments, and experiences shape our brain health and learning capabilities.During this episode, Dr. Boyd guides us through the science behind neuroplasticity, highlighting the brain's inherent ability to rewire itself and learn new skills at any age. She emphasises that everything we do and encounter is continuously shaping our brains.Her work focuses on the impact of exercise and learning on our neurobiology, showcasing the profound effects these activities have on optimising our brain function. Dr. Boyd's research sheds light on how we can leverage our physical bodies to access and enhance different states of mind.In a world where stress, anxiety, and burnout are prevalent, Dr. Boyd's insights offer a beacon of hope for better self-regulation and human evolution. She shows us that we have the power to shape our brains in ways that align with our desires and aspirations."We only have one brain. We can shape it however we choose. So go out and build the brain you want." - Dr Lara BoydTimestamps:00:00:00 - Introduction00:00:50 - Background To Dr Boyd00:01:27 - What drove Dr Boyd's focus on Neuroplasticity & Human Physiology00:03:53 - How do we learn?00:05:25 - Misconceptions about Neuroplasticity?00:07:56 - White Matter, Human Critical Physiology and Anatomy00:13:00 - Can a Vaccine for The Epstein–Barr Virus Prevent Multiple Sclerosis?00:14:27 - Short vs. Long Term Memory Loss & Damage00:17:04 - Why Some People Find Learning Easier Than Others?00:23:44 - Trauma & Priming The Brain To Drive Neuroplasticity00:27:10 - Lessons from Post Stroke Trauma Studies, Neuroplasticity and Wider Society Learnings00:30:33 - The Study of Biomarkers & Remarkable Results00:35:37 - A Modern Epidemic (Stress, Anxiety, Burnout & Mental Health) & Relievers (Exercise, Cortisol, Growth Factors & The Bluezones).00:41:41 - A Study Between Runners and Yogi's & The Results00:45:47 - A Study on Burnout (Teachers, the NHS and beyond).00:48:00 - Personalised Medicine & Personalised Learning00:49:50 - AI, Concerns & The Evolution of Healthcare00:51:39 - The Broader Implications of Findings on Neuroplasticity in terms of Life Long Learning, Addiction & Behavioural Change?00:55:06 - Closing Thoughts & Key TakeawaysEnjoyed the podcast? Subscribe nowWatch on YouTubeConnect: Peter Bell, Dr Lara BoydInterested in becoming a sponsor or collaborating with us, reach out via Purpose Made. Your support helps us continue delivering the thought-provoking content to our audience.This podcast was recorded and produced by Purpose Made. Join our tribe and lets grow together https://plus.acast.com/s/purpose-made-podcast. Hosted on Acast. See acast.com/privacy for more information.

#239Two decades ago, following the Human Genome Project's release of a first draft in 2001, genetic testing was set to revolutionise healthcare. “Personalised medicine” would give us better treatments for serious conditions, clear pictures of our risks and individualised healthcare recommendations. But despite all the genetic tests available, that healthcare revolution has not exactly come to fruition. Amid news that genetic testing poster child firm 23andMe has hit financial troubles, we ask whether personalised medicine was overhyped.Ancient Greek philosopher and mathematician Pythagoras once established strict mathematical rules for what constitutes pleasing music – those rules involve ratios and harmonies that were the basis of much of Western music theory. But comprehensive new research finds people's preferences have little to do with Pythagoras' rules.The invention of the numeral zero to represent nothing is a cornerstone of some of our greatest accomplishments as a species, like calculus, literature and philosophy. Now researchers have figured out how our brains comprehend the idea of nothing – and it may have started as registering the absence of predators, prey, or even weather conditions. The experiment finds where “nothing” lives in our brain and traces back the invention of the numeral zero to our animal roots.If you want to make friends with a dog but are wary of petting them, there is a way. All you need to do is follow them around and copy their movements. Research into this behavioural synchronisation could prove beneficial to helping nervous pups connect better with people.Plus: Making plankton poo heavier with clay – for the environment; YouTube's recommendation algorithm seems to have stopped inadvertently radicalising people; the specific chemical compounds that make an orange taste orangey.Hosts Christie Taylor and Timothy Revell discuss with guests Clare Wilson, Jacob Aron, James Woodford and Sam Wong. To read more about these stories, visit newscientist.com.Music credit:“Bonang,” Wesleyan University Virtual Instrument Museum 2.0, accessed February 29th, 2024, https://wesomeka.wesleyan.edu/vim2/items/show/3 Hosted on Acast. See acast.com/privacy for more information.

BNR Beter is terug! Het programma over innovaties in de zorg. Dit is de eerste aflevering van een gloednieuw seizoen. In dit programma focussen we ons op de zorg van MORGEN, waarin er – hopelijk - nóg betere zorg kan worden geleverd met behulp van nieuwe technieken, digitalisering én natuurlijk met de onmisbare handen aan het bed. Hoe maken we de zorg elke dag BETER?    Medicatie  Een onmisbaar element in de zorg is medicatie: maar pillen en tabletten zijn voor volwassen patiënten ontworpen. Voor kinderen is het samenstellen van de juiste medicatie een enorme opgave. Zij kunnen niet de volwassenendoses slikken. En dan is er ook nog het hele slik-probleem. Voor de meeste kinderen is het al ingewikkeld om een paracetamolletje door te slikken. Zelfs als die een 'lekker' smaakje hebben. Laat staan een halve hand vol verschillende pillen, wat voor ernstig zieke kinderen wel nodig is.   De oplossing die hier nu meestal voor bedacht wordt is vaak dat het medicijn opgelost wordt in een drankje. Maar ook daar zijn allerlei problemen mee: kinderen vinden het nog steeds niet lekker, de drankjes zijn minder lang houdbaar en er zijn allerlei risico's dat er alsnog verkeerde dosering wordt gegeven.     3D-pillen printer  Het Leids Universitair Medisch Centrum (LUMC) heeft samen met fabrikant Doser een innovatieve oplossing bedacht. Zij kunnen met een high tech 3D-pillen printer hele kleine tabletjes maken, perfect op maat voor kinderen. Een paar drukken op de knop en twintig minuten later liggen er twintig tabletjes ter grote parelcouscous klaar voor de patiënt.   Ziekenhuisapotheker Kirsten Schimmel van het LUMC vertelt hoe het gaat met het onderzoek naar deze pillenprinter. Zij leidt het project en begeleid promovendi en studenten die onderzoeken welke dosering het beste werkt en welk hulpmiddel nodig is.   Kindercardioloog Derk Jan ter Harkel vertelt hoe hard deze middelen in zijn praktijk nodig zijn. Hij behandelt kinderen met hartproblemen uit het hele land. Zolang hij drankjes moet voorschrijven die in het LUMC gemaakt worden, moeten ouders elke drie weken naar het LUMC komen om het drankje te halen. 'Rondom vakanties is het helemaal een logistieke uitdaging.'      Over BNR Beter   In BNR Beter – over de zorg van morgen laten we zien welke oplossingen er bedacht worden. Hoe deze in de praktijk uitpakken en hoe patiënten en zorgprofessionals hiermee geholpen worden.   Nina van den Dungen interviewt de uitvinders van de nieuwste zorginnovaties en ze spreekt specialisten en verpleegkundigen wiens werk verlicht worden door deze innovaties. Nina gaat samen met redacteur Sterre ten Houte de Lange op reportage naar de ziekenhuizen, UMC's, zorginstellingen en laboratoria en testruimten waar deze nieuwe technieken worden ontworpen of voor het eerst worden ingezet in de patiëntenzorg.   De vraag die we ons elke aflevering stellen: wat is het probleem waar de zorgprofessionals en patiënten tegenaan lopen? Wat is de oplossing die bedacht is? Is deze oplossing efficiënter, effectiever en goedkoper? Hoe kijken de behandelend artsen naar deze ontwikkelingen? Lukt het om de innovaties te implementeren? Welke obstakels komen de wetenschappers, uitvinders.     Over de makers  Presentatie door Nina van den Dungen. Nina is journalist en presentator bij BNR Nieuwsradio. Redactie door zorgjournalist Sterre ten Houte de Lange.   See omnystudio.com/listener for privacy information.

Many of the latest anti-cancer drugs are targeted towards the tiniest molecular differences in cells. But even if you know the genetic make up of a tumour, getting medicines to - and then in to - the affected area is a different challenge.Dr Moutih Rafei at Defence Therapeutics reports on a novel drug technology that gets more treatment to the cells that need it,  and what that might mean for the future of designing, trialling, and marketing medicines.Read the original research: https://doi.org/10.1111/cas.15985

Atlantic Technological University (ATU) will co-lead a research project looking into how 3D printing can transform healthcare through personalised medicine. The PROCEED 3D (Process Control for Extrusion-based 3D-printing of Personalised Medicine) project is co-led by Dr Marion McAfee, ATU's senior lecturer and Dr Rabah Mouras and Prof Gavin Walker at the University of Limerick. As the world's population ages and the one-size-fits-all approach to medicine is often inadequate, 3D printing of personalised medicine could be a game-changer in tailoring healthcare solutions, particularly for the elderly population, as it offers a new level of precision and personalisation in treatment by including several drugs in a single tablet at customisable doses. This approach improves treatment outcomes and empowers healthcare providers to create patient-centric solutions to enhance overall well-being. One of the key benefits is for older people, says project lead Dr Marion McAfee: "Personalised medicine is all about tailoring therapy to the individual patient's specific needs, taking into account their age and gender and their body mass, and the fact that they might have multiple conditions that all need treatment. With 3D printing, we can print the pill and combine all the drugs that a patient needs in a single pill that they take once a day, making it safer and easier for them, instead of taking multiple different pills each day and trying to remember which pill to take and when which could result in several problems for the patient". She adds: "3D printing could be the key technology in such cases because it allows us to develop a pill or medical implant specific to that patient's needs, available to them in their local pharmacy or hospital."

It took ten countries ten years and $3 billion to sequence the human genome but since that seismic breakthrough the time, cost and effort to repeat the feat has plummeted.Dr Euan Ashley, Associate Dean in the School of Medicine at Stanford University, is known for helping establish the field of medical genomics and led the team that conducted the first medical interpretation of the human genome.Most recently his team have held a Guinness World Record for the fastest DNA sequencing technique at a little more than five hours.The implications, as he explains in an in-depth conversation with Unfiltered editor-in-chief Joe Warner, will change the world, both in extremely rare cases of unknown disease diagnosis for faster treatment, right up to population-level systemic changes to national and international healthcare policy.It has the potential to change everything we thought we knew about genetics, disease, medicine and treatment, and could significantly improve both lifespan and healthspan around the world.But it is not without risk, most notably the concern of the creation of a multi-tier healthcare and insurance system in which those with money and influence will always be at the front of the queue.As Dr Ashley explains, the future of the world rests on the right decisions being made.For exclusive access to all Unfiltered's video interviews, features and documentaries visit https://unfilteredonline.com/Get in touch in the comments below or talk to us on:Email: editorial@unfilteredonline.comYouTube: https://www.youtube.com/channel/UCGSV7XVaBYUYq5YidLI12owInstagram: https://www.instagram.com/unfiltered.extraTwitter: https://twitter.com/UnfilteredExtra

Christian Gratzke sits down with Brant Inman to discuss the special Issue Brant Guest Edited which looked at Personalized Medicine in Genitourinary Oncology. Also available on our YouTube channel

MMC Principal, Charlotte Barttelot, leads our focus on data-driven health investments. In this episode, she interviews Patrick Short, founder and CEO of Sano Genetics - an MMC portfolio company that connects patients directly with biotech and pharmaceutical companies, accelerating research on rare and chronic diseases. The dramatic reduction of cost and time to sequence the human genome has led to the acceleration of personalised medicine. Charlotte and Patrick discuss the impact this has on the evolution of the drug development process, the change in attitude to the use of personal data, and how important the move towards greater trust and transparency in the industry is.

Silke Gillessen, Director of the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, joins Jonathan to discuss her specialty of genitourinary oncology, and why personalised and precise treatment is so vital.  Listen to the following timestamps to navigate the content in this episode: (00:00)-Introduction  (03:10)-Gillessen's origin story  (04:25)-Differences and similarities in access to care between countries  (06:26)-Inspiration to start the medical oncology unit for genitourinary cancer Kantonsspital St. Gallen  (08:16)-Gillessen's experience in the UK  (11:00)-How evidence-based medicine can best influence adoption of ESMO guidelines  (14:18)-The meaning of precision oncology and novel treatments for prostate, testicular, and penile cancers  (17:17)-How ESMO can help support patients dealing with a cancer diagnosis  (20:47)-Treatment for patients with castration-resistant prostate cancer  (23:52)-Optimising treatment for metastatic prostate cancer  (25:51)-Molecular targeted drugs and immunotherapy in prostate cancer  (27:40)-Three wishes

As Season 5 of the GOLD podcast approaches its end, join Isabel and Jade as they share some of the most memorable moments from the last couple of months.  Join our hosts for a trip down memory lane as they look back on their ‘GOLD Medal Moments' in the penultimate episode of the season. They cover topics such as the importance of avoiding tokenism, the value of personalisation, investing in customer experience and much more.  If you're interested in learning more about the topic areas discussed in this episode, check out the following content:   My journey with diversity, equity and inclusion https://www.emg-gold.com/post/my-journey-with-diversity-equity-and-inclusion  Cell and gene therapy: a victim of its own success  https://www.emg-gold.com/post/cell-and-gene-therapy-a-victim-of-its-own-success  Mapping a path to personalised medicine https://www.emg-gold.com/post/mapping-a-path-to-personalised-medicine  Conquering generational differences in HCP marketing https://www.emg-gold.com/post/conquering-generational-differences-in-hcp-marketing  Upgrading the personal touch in CX https://www.emg-gold.com/post/upgrading-the-personal-touch-in-cx 

This month join host Dr Chris Smith to hear how a nuclear power station provides the opportunity to test theories of the effects of global warming on how fish grow, evidence that personalised medicines have an added placebo effect, the genes for skin colour and skin cancer, why five friends is optimal for best brian health, and the role of the immune system in the ageing ovary... Get the references and the transcripts for this programme from the Naked Scientists website

In this week's episode, Isabel and Jade share some snippets from the interview with GOLD's next catalyst Karen Pinachyan, Head of Medical Affairs, Europe, CSL Behring.   In this teaser edition of the full interview, Karen shares his motivation for joining the pharmaceutical industry, his thoughts on how to shift the care paradigm towards personalised medicine and how he believes both industry and healthcare systems can work together to deliver more value to patients.   If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Mapping a path to personalised medicine Revealing the true value of medical affairs Podcast: Is medical affairs the Ferrari of the pharma industry? Last week's episode: Shaping success in cell therapy

Join Patrick in welcoming Dr. Bettina Lundgren, CEO of the Danish National Genome Center. Bettina is spearheading the development of personalised medicine in Denmark with a focus on integrating genome sequencing directly into the healthcare system. She is dedicated to fostering international collaboration in research and healthcare delivery. Tune in to learn about the one of the leading national scale genomics initiatives, and Bettina's r insights on the future of personalised medicine! 0:00 Intro 0:56 Bettina's path to genomics 1:47 Aspirations of the Danish National Genome Center 4:18 Comparing the Danish National Genome Center to other global genomics programs 8:10 Goal to sequence 60,000 whole genomes by 2024 11:40 The biggest challenges of integrating genomics with healthcare 15:30 Navigating the politics of privacy and data sharing 20:02 Complexities of sharing data across diverse regions and healthcare systems 23:28 Partnerships across borders: Sweden, Europe, and the world 28:10 Looking forward 10 years: strategies and novel developments in personalised healthcare 31:25 Final Thoughts 32:37 Outro

Join Patrick in welcoming Dr. Bettina Lundgren, CEO of the Danish National Genome Center. Bettina is spearheading the development of personalised medicine in Denmark with a focus on integrating genome sequencing directly into the healthcare system. She is dedicated to fostering international collaboration in research and healthcare delivery. Tune in to learn about the one of the leading national scale genomics initiatives, and Bettina's r insights on the future of personalised medicine! 0:00 Intro 0:56 Bettina's path to genomics 1:47 Aspirations of the Danish National Genome Center 4:18 Comparing the Danish National Genome Center to other global genomics programs 8:10 Goal to sequence 60,000 whole genomes by 2024 11:40 The biggest challenges of integrating genomics with healthcare 15:30 Navigating the politics of privacy and data sharing 20:02 Complexities of sharing data across diverse regions and healthcare systems 23:28 Partnerships across borders: Sweden, Europe, and the world 28:10 Looking forward 10 years: strategies and novel developments in personalised healthcare 31:25 Final Thoughts 32:37 Outro

Explore the industry's evolving mission to advance cancer research and care in this new episode of the GOLD podcast with hosts Isabel and Jade, featuring an insightful conversation with Dr Sunil Verma, Global Head of Oncology, Medical, AstraZeneca.    In this episode, Isabel uncovers Sunil's passion for working in oncology, his analysis of where cancer care has been and where it is going, why personalised medicine is the ultimate goal for oncology and an insight into the challenge that can keep him up at night.  

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW's Megan Thomas is in conversation with Dr Pierre Eftehkari, the Chief Sceitnific Officer of Inoviem Scientific. With more than 15 years of experience in drug development, Dr Eftekhari has gained an in-depth understanding of the pharmaceutical industry and its needs. He focuses on enhancing genetically guided personalised medicine with the goal of providing safer and more effective therapies that are accessible to everyone. In this episode, Dr Eftekhari shares his insight into the future of drug development. 

Our latest podcast tackles a timely and groundbreaking topic of personalised medicine with Piret Hirv, the manager of the Connected Health Cluster. Piret, with her background as a trained nurse and experience in the Ministry of Social Affairs, brings valuable insights into the importance of private and public partnerships, the future of behavioural health, and the current status of personalised medical services in Estonia.

In this episode of Run with Fitpage, we had the pleasure of hosting the world's leading genomicist - Dr. Michael Snyder. Vikas and Dr. Snyder talk about CGMs and other variables in one of the most insightful conversations of Run with Fitpage so far.Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. He received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. Dr. Snyder has pioneered the use of “big data” and multi-omics to advance scientific discovery and transform healthcare. His laboratory has invented many technologies that are widely used in medicine and research, including methods for characterizing genomes and their products (e.g. RNA-Seq, NGS paired-end sequencing, ChIP-Chip and later Chip-Seq, protein arrays, machine learning for disease gene discovery).Snyder Lab was the first to perform a large-scale functional genomics project in any organism and has developed many technologies in genomics and proteomics. He has also co-founded January AI and Iollo. Listen to this episode with a pen and paper to learn more about Continous Glucose Monitoring and much more!Important resources from the episode:innovations.stanford.edu/wearablesq.biowww.iollo.comwww.january.aiRead more about Dr. Snyder's Research here.About Vikas Singh:Vikas Singh, an MBA from Chicago Booth, worked at Goldman Sachs, Morgan Stanley, APGlobale, and Reliance before coming up with the idea of democratizing fitness knowledge and helping beginners get on a fitness journey. Vikas is an avid long-distance runner, building fitpage to help people learn, train, and move better.For more information on Vikas, or to leave any feedback and requests, you can reach out to him via the channels below:Instagram: @vikas_singhhLinkedIn: Vikas SinghGmail: vikas@fitpage.inTwitter: @vikashsingh1010Subscribe To Our Newsletter For Weekly Nuggets of Knowledge!

To mark the final episode of Season 4, Isabel and Jade reminisce about their favourite moments from the series and give an exclusive teaser for the next issue of GOLD – out on 13 April.   Expect discussion on topics such as the current state of life sciences innovation in the UK, the latest advances and potential of personalised medicine, a deep dive into our Catalyst interview with Christi Shaw, former CEO, Kite Pharma, and lots of bonus insights from the writers themselves.    Be sure to subscribe here to receive the full issue straight to your inbox on publication day.  

In her book 'Advancing Healthcare Through Personalized Medicine', science writer Dr Priya Hays has compiled an authoritative and highly detailed account of how technology is changing healthcare. Read more in Research FeaturesRead it now at :https://doi.org/10.1007/978-3-030-80100-7 

Hello and welcome to the latest episode of OC Talks, the podcast from Oncology Central. I am Jade Parker, Senior Editor of Oncology Central. Today I am joined by Laetitia Decroix Guilloux, Vice President of Oncology and EMEA Commercial Strategy Lead at Janssen, to discuss the patient journey through lung cancer, examine the lung cancer paradigm, and how the cancer research community can holistically address unmet needs in cancer.

One of the many inspiring speakers at the Integrative and Personalised Medicine conference this year was Patrick Holden, Founding Director and Chief Executive of the Sustainable Food Trust. Patrick's session really resonated with me as he shared his passion about the application of Nature's principles of Harmony to food and farming. I am thrilled that Patrick agreed to join me in a podcast this season to discuss why our food system is in desperate need of reform. With nearly 50 years of farming experience, Holden Farm Dairy is now the longest established organic dairy farm in West Wales. As well as being hands-on at the farm, his role at the Sustainable Food Trust works towards accelerating the transition towards more sustainable food systems and influencing government policy - he only recently returned from COP27. I'm so grateful to Patrick for his time to talk about how sustainable food systems directly impact our health - there's plenty that we can all learn and do to support sustainability.

This podcast is part of a miniseries of interviews with speakers from the 2022 annual conference of the Adelphi Genetics Forum - a learned society that aims to promote research and discussion concerning the scientific understanding of human heredity. Formerly known as the Galton Institute, and before that, the Eugenics Education Society, the society has changed its name to the Adelphi Genetics Forum to firmly reject and distance itself from the discredited and damaging ideas of its namesake, Francis Galton – widely viewed as the founder of eugenics.Anneke Lucassen is Professor of Genomic Medicine & Director of the Centre for Personalised Medicine at the University of Oxford and Professor of Clinical Genetics at the University of Southampton. Her talk, titled “Genomic Medicine, Diverse Data and the Language of Race, Ancestry and Ethnicity” explored the issues caused by a lack of diversity in genomic databases, and the challenges of addressing this in a way that doesn't cause additional injustice and harm. Kat Arney started by asking why it's so necessary to do this work.You can find out more about the Adelphi Genetics Forum, including their grants, awards and publications, at adelphigenetics.org You can check out the rest of this series on the Genetics Unzipped podcast feed – just search for Genetics Unzipped on Spotify or wherever you get your podcasts. This series was produced by the team at First Create The Media – that's Kat Arney, Sally Le Page and Emma Werner, with help from Ed Prosser and Frankie Pike. Our music is Drops of H2O by J. Lang, licensed under Creative Commons.

Personalised medicine is the future. We live in a world of AI and machine learning and the expectation of medicine is to be more precise. Can we get half way there ourselves by thinking about things a certain way? How do we get to the root cause?Leroy Hood: https://isbscience.org/bio/leroy-hood/P4 medicine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204402/The counterpoint to P4 medicine: https://academic.oup.com/jalm/article/4/1/108/5603054David Unwin's work on type 2 diabetes: https://collegeofmedicine.org.uk/our-beyond-pills-campaign-dr-david-unwin-on-beating-diabetes-with-diet-and-how-his-own-merseyside-practice-has-saved-68000-a-year-on-drugs/Group consultations:https://www.england.nhs.uk/gp/case-studies/group-consultations-together-patients-are-stronger/Leafyard: AI driven mental health app (COI: I am in a partnership with Leafyard): https://www.leafyard.com/healthfix Hosted on Acast. See acast.com/privacy for more information.

Douglas Reil is the co-founder and CEO at CannaKeys, whose mission is to empower patients, medical professionals, caregivers, and the industry with the tools to maximize the effectiveness of cannabis therapeutics and create an agency with regard to their applications. In this episode, Doug talks openly about his combined experience as a patient and work in the publishing industry that led to the creation of CannaKeys. In addition, he describes his vision for a new clinical model that would offer a science-based holistic, individualised approach using plant-based therapies and mind-body medicine.He is motivated to drive this mission by his experience working with patients and as his own path incorporating cannabis to help treat his Crohn's Disease. In the cannabis industry, he has worked in compliance and community development and was the Program Director of the compassion program Mission: Compassion which provided free cannabis medicine to low-income patients. He was a founding member of the California Compassion Coalition which drove the passage of SB34 which created compliant pathways for compassionate cannabis activities in California. His thirty- five year career in publishing includes serving as Publisher and Executive Director at the nonprofit publisher North Atlantic Books and currently as Associate Publisher and Managing Director at Synergetic Press which focuses on psychedelics, regenerative practices, and social justice. Useful Linkshttps://www.linkedin.com/in/douglasreil/https://synergeticpress.com/https://cannakeys.comhttps://www.facebook.com/douglas.reil To learn more about plants & your health from Colleen at LabAroma check out this informative PDF https://mailchi.mp/2fe0e426b244/osw1lg2dkh Disclaimer: The information presented in this podcast is for educational purposes only and is not intended to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.

DDK Pod Episode 27. Personalised Medicine.  We increasingly live in a world where technology is enabling concepts such as individually tailored medical treatments to become reality.  The balance of cost effectiveness is often not quite there yet, but it isn't far off.  We take a look at some of the methods used to personalise medical interventions, and look towards the future when the ubiquity of technologies like genome sequencing could make personalised medicine the new normal.   Also covered is our pick of the IT industry news and a few recommendations for our listeners.               Timecodes: 00:36 - The News 08:20 – Personalised Medicine 36:08 - DDK Recommends Stuff43:10 - Get in touch              Get in touch with the show: Email us ddkpod@ddklimited.comTweet us: @ddklimitedOur Website: www.ddklimited.comFind us on LinkedIn: DDK LimitedAudio edited by Charlie McConville, www.interflowcreations.co.uk

Personalised medicine tailored to the individual's health needs is not exactly new, but it's a field that's rapidly growing and garnering much attention in various fields of health, especially in cancer treatment. On this episode of Brain Waves, we break down the role of genetics in personalised medicine and the future of personalised medicine in neurological diseases, with Dr Azlina Ahmad Annuar, neurogeneticist, and Dr Ruth Chia from Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging.

Estelle as a new mother, during her pregnancy, had experienced what many other women have to go through having to manage multiple appointments, measure her blood pressure multiple times a day and medication incompatibilities. She realised that these issues were not uncommon and although there existed many apps and tools, there was nothing available to help manage her own health during this time period. Having started her career in academia as a professor at The University of Western Australia and then transitioning to industry working at Illumina within Genomics, she used her knowledge to co-found Trellis Health to create lasting change and reframe the way pregnant mothers take control of their care. On this episode she discusses how throughout the seventies up until the nineties, how women were excluded from clinical trials hence why the data has not always existed to create viable solutions for female health, the reality of genetics in terms of what is seen in movies separating fact from fiction, the emerging technologies we can look forward to seeing in terms of data science and genomics, her journey through pregnancy leading to the formation of Trellis Health, needs in female healthcare, what the gaps in the market currently are within Femtech and the empowering nature of remaining curious and the opportunities it can bring. Get in touch with Estelle Giraud https://www.linkedin.com/in/estelle-giraud/ or visit her company website https://www.jointrellishealth.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/c/QRAMedical

The cancer risks that run through generations of families—and the growing frontier in medicine trying to change that.

In this week's episode Patrick is joined by Michael Spigler, Vice President of Patient Support and Education at American Kidney Fund. They discuss how making genetic testing mainstream could significantly improve patient outcomes, why black Americans are four times more likely to experience chronic kidney failure, and what can be done to reduce the number of patients needing dialysis.

In this week's episode Patrick is joined by Michael Spigler, Vice President of Patient Support and Education at American Kidney Fund. They discuss how making genetic testing mainstream could significantly improve patient outcomes, why black Americans are four times more likely to experience chronic kidney failure, and what can be done to reduce the number of patients needing dialysis.

Years ago, Dr Bhatt, an early adopter of telemedicine, had difficult news for her patient that she wanted share with him in person. Her patient was resistant and they scheduled a video meeting. The patient asked Dr Bhatt to let him hear the news surrounded by his family in the safety of his home. Dr Bhatt learnt that she needed to listen to patients about how they want to be told things and how these interactions might effect them. This week's guest on Parallax is Dr Ami Bhatt, Chief Innovation Officer of ACC, Associate Professor at Harvard Medical School and Director of the ACHD program at Massachusetts. In this engaging and in-depth episode, Dr Kalra and Dr Bhatt talk about the state of digital transformation today: They discuss the challenges and opportunities of telemedicine, artificial ‘collaborative' intelligence and novel technologies that could enhance medical training. Dr Kalra asks Dr Bhatt about how she balances her responsibilities and her tips for approaching complex problems. Dr Bhatt also shares insights on the practicalities of her role as Chief Innovation Officer of ACC. What is the next frontier in cardiovascular medicine? How can we best utilise available technology in medicine? What is Dr Bhatt's advice to our audience? Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest, Dr @AmiBhattMD hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

6 May 2022 - The amazing advances in gene sequencing technology over the last two decades have not yet sparked the revolution in personalized cancer treatment that many had hoped for. Although there have been significant advances,  actionable mutations, those that can be targeted to improve patient survival or quality of life, remain rare. But there is also the option to leapfrog genomics entirely, or to complement it, by using proteomic approaches. You may be surprised to learn that, as the guests on this episode of our podcast, Ursula Klingmüller and Matthias Mann told us, clinical proteomics is already being explored to design personalized cancer treatment strategies. Klingmüller and Mann discussed the technological (read the Mann lab's recent Molecular Systems Biology paper on single cell proteomics here), scientific, and clinical challenges of the field with Molecular Systems Biology Senior Scientific Editor Maria Polychronidou.

In this Healthy Bite, we are going to focus on personalised medicine. If you listen to your body, look back and review your family history, and we do get this report card in every single day, which gives us a clue as to how healthy we are, how our digestive system is doing, whether we are in good balance with our microbiome. Tune in as we also discuss the highlights of my conversation with Gerald Quigley. ----  You can also watch this episode at https://drronehrlich.com/  ----- TIME TO TAKE CONTROL OF YOUR HEALTH? Join me in my online health programs.  ----- CONNECT WITH ME You can ask questions via social media using my Instagram or Facebook or TikTok or YouTube page. See omnystudio.com/listener for privacy information.

Today we welcome practitioner business mentor Tammy Guest to Wellness by Designs. Listen in as Tammy reveals the many opportunities practitioners have to create a personalised practice that amplifies your gifts and talents, which manages your energy and your health and works for you rather than you working for it.About Tammy: Hey There! I'm Tammy Guest.Business Mentor, Speaker, Author, Facilitator and Freedom-Seeker.It's my mission to amplify the mindset, lifestyle and possibilities for change-makers like you, so that you can go out there and activate change for your clients, yourself and the world.My passion lies in facilitating the expansion of possibility for driven entrepreneurs. Through guided mentoring and immersive experiences, I drive your ability to create a business and a lifestyle that is beautifully aligned to you and allows you the perfect environment to create, innovate, and lead in ways you haven't been able to.Connect with Tammy:  https://www.tammyguest.comShownotes and references available on your local Designs for health website www.designsforhealth.com.au Discover quality practitioner only supplements at www.designsforhealth.com.auDISCLAIMER: The Information provided in the Wellness by Designs podcast is for educational purposes only; the information presented is not intended to be used as medical advice; please seek the advice of a qualified healthcare professional if what you have heard here today raises questions or concerns relating to your health

How can precision medicine techniques be used to develop potential new treatments for genetic Parkinson's disease? In the latest episode of our Precision Pioneers miniseries, Patrick speaks to Dr Carrolee Barlow, Chief Medical Officer at ESCAPE Bio, about the challenges of accessing genetic testing for Parkinson's patients, how genetically guided treatments could help patients with the LRRK2 gene, and how new technologies such as wearable devices could help catch Parkinson's cases at an earlier stage.

In this episode, we imagine a future where medical decisions in India are personalised for our DNA; where treatments are tailor-made for our individual genetic makeup. Why? Because not everyone responds in the same way to any given medical treatment. A painkiller that seems to work for your friend, might not work for you. An anti-diabetic medication that works for your father, might not work for your mother. As researchers are finding out, our genes could hold the answer. Our individual genetic makeup can have a role to play in what diseases we develop; how our bodies metabolise medicines; and what treatments work or don't work for us. If we know how and which genes influence our health, can we develop treatments to target those genes? Do we even know enough about genetic variations within Indian populations and how these variations relate to different diseases or disorders? And can we harness this knowledge to find personalised treatments in the near future? Read the episode transcript here. Imagined Tomorrow is created and hosted by Shreya Dasgupta. The episode was co-edited by Abhishek Madan. Intro and outdo music is by Abhijit Shylanath. Get in touch via Twitter, or email imagined.tomorrow@gmail.com. Guests: Shambhavi Ravishankar is a lawyer who lives with a rare genetic disease called Alagille Syndrome. She's an associate at Ikigai Law. Berty Ashley is a molecular geneticist at Dystrophy Annihilation Research Trust (DART) who loves music and science. Anu Acharya is the founder and CEO of Ocimum Bio Solutions, and Mapmygenome, a personal genomics company. Dr. Bhawna Sirohi is a cancer specialist with expertise in breast and gastrointestinal cancers at the Apollo Proton Cancer Centre in Chennai Episode music: Interlude music by 1tamara2, enrique27naveda and Zen_Man from Pixabay Episode artwork: Image by Gordon Johnson from Pixabay

Everyone is different, and treatment options increasingly reflect that. As we understand more about our genetic makeup, our varying response to conventional therapies means that we can design drugs and build devices tailored for individuals ('bespoke' rather than 'ready made'). This lecture considers the challenges that the NHS and its suppliers face in employing personalised medicine.The transcript and downloadable versions of the lecture are available from the Gresham College website: https://www.gresham.ac.uk/lectures-and-events/personalised-medicine-made-for-youGresham College has been giving free public lectures since 1597. This tradition continues today with all of our five or so public lectures a week being made available for free download from our website. There are currently over 2,000 lectures free to access or download from the website.Website: http://www.gresham.ac.uk Twitter: http://twitter.com/GreshamCollege Facebook: https://www.facebook.com/greshamcollege Instagram: http://www.instagram.com/greshamcollege